Boehringer Ingelheim Animal Health announces the 2014 European PRRS Research Award

• A total of 75,000 euros to fund three research projects against swine disease
PRRS
• Open for submissions until July 18, 2014


Ingelheim, Germany – WEBWIRE – Wednesday, April 30, 2014

Boehringer Ingelheim Animal Health reinforces its commitment to support applied research for the improved control of PRRS (Porcine Reproductive and Respiratory Syndrome) in Europe. To continuously provide practical approaches to the management of the disease, Boehringer Ingelheim announces the 2014 European PRRS Research Award. This commitment will provide three grants of 25,000 euros each to fund research proposals that will generate new and practical information to better understand this devastating disease. PRRS virus infects pigs around the globe causing reproductive failure in breeding stock and respiratory tract illness in growing pigs. As a result, swine farmers worldwide have to cope with suffering and death cases among their animals together with an economic damage. Boehringer Ingelheim strives to find solutions to control PRRS.

The objectives of this initiative are to encourage research resulting in practical application of PRRS control strategies and the interaction among swine researchers and veterinarians as well as to enhance communication in the industry on practical PRRS control strategies and to reward research excellence.

Applications to submit research proposals can be made on www.europeanprrsresearchaward.com. The deadline for this year’s submissions is July 18, 2014. Any person involved in the swine industry in Europe including Russia is eligible to submit proposals for consideration.

Each proposal will be reviewed by an independent review board of highly recognized swine industry professionals including researchers and practitioners:

Dr. Enric Mateu, Universitat Autonoma de Barcelona (Spain)
Dr. Lars Erik Larsen, National Veterinary Institute DTU Vet (Denmark)
Dr. Giampietro Sandri, Gruppo Veronesi (Italy)
Dr. Albert Vidal, Vall Companys (Spain)
Dr. Tomasz Stadejek, Warsaw University of Life Sciences (Poland)
Dr. Enric Marco, Private Practice and EAPHM (European Association of Porcine Health Management) (Spain)
Dr. Michael Murtaugh, University of Minnesota (USA)

The independent review board will select proposals based on the criteria such as significance, potential for impact to the swine industry or originality and innovation.

The recipients of this year’s European PRRS Research Award will be announced in October 2014.

Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 142 affiliates and a total of more than 47,400 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Taking social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2013, Boehringer Ingelheim achieved net sales of about 14.1 billion euros. R&D expenditure corresponds to 19.5% of its net sales.

For more information please visit www.boehringer-ingelheim.com



WebWireID187427





This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.